Access cutting-edge glioblastoma treatment through this clinical trial at a research site in Palo Alto. Study-provided care at no cost to qualified participants.
Access glioblastoma specialists in Palo Alto at no cost
This study follows strict safety protocols and ethical guidelines
All study-related glioblastoma treatment provided free
This is a multicenter, two-arm, randomized, double-blind, placebo-controlled study of Optune® (Tumor Treating Fields at 200 kHz) together with maintenance Temozolomide (TMZ) chemotherapy agent and pembrolizumab compared to Optune® together with maintenance TMZ and placebo in newly diagnosed Glioblastoma (GBM) patients. The primary objective of the study is to evaluate the Overall Survival (OS).
Sponsor: NovoCure GmbH
Check if you qualify for this glioblastoma clinical trial in Palo Alto, CA
If you're searching for glioblastoma treatment options in Palo Alto, CA, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Palo Alto research site is actively enrolling participants for this clinical trial. You'll receive care from experienced glioblastoma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.